Holen Sie sich die Stockscreener-App
0.9563
16.57%
0.1359
Handel nachbörslich:
.98
0.0237
+2.48%
Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten
Franklin Resources Inc. Acquires Additional Shares in Context Th - GuruFocus.com
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MSN
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted Therapy - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update - MarketBeat
Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too - MSN
Context doses first subject in Phase I cancer trial of CTIM-76 - Yahoo Finance
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from D. Boral Capital - MarketBeat
Context Therapeutics Advances CTIM-76 in Clinical Pipeline - TipRanks
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 - GlobeNewswire
Context Therapeutics Launches Phase 1 Trial for Novel Cancer Treatment CTIM-76 - StockTitan
Context Therapeutics Appoints Andy Pasternak as Chairman - TipRanks
Context Therapeutics appoints new chairman Andy Pasternak - Investing.com India
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors - The Manila Times
Context Therapeutics Names Former Horizon Executive Andy Pasternak as Board Chairman - StockTitan
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.80 Average Target Price from Brokerages - Defense World
Geode Capital Management LLC Cuts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Geode Capital Management LLC Purchases 70,070 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
JMP Securities Begins Coverage on Context Therapeutics (NASDAQ:CNTX) - Defense World
Context Therapeutics (NASDAQ:CNTX) Raised to Strong-Buy at Citizens Jmp - Defense World
MPM BIOIMPACT LLC Acquires Significant Stake in Context Therapeu - GuruFocus.com
Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Citizens Jmp - MarketBeat
SpringWorks Therapeutics Stock Gets A RS Rating Lift - MSN
Aclaris Therapeutics Awards Stock Options to Attract Top Talent - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Earns Outperform Rating from Analysts at JMP Securities - MarketBeat
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Analyst sees upside in Context Therapeutics stock—next-gen antibodies in spotlight - Investing.com Nigeria
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Philly’s year in biopharma: a look back at 2024 - MSN
State Street Corp Purchases 19,800 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Cal-Maine Foods IN (CALM-Q) QuotePress Release - The Globe and Mail
APLT INVESTOR NOTICE: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - The Malaysian Reserve
Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Expands By 22.9% - MarketBeat
Context Therapeutics to Engage Investors at November Conferences - MSN
Applied Materials (AMAT-Q) QuotePress Release - The Globe and Mail
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment - Benzinga
Unpacking Q3 Earnings: Netflix (NASDAQ:NFLX) In The Context Of Other Consumer Subscription Stocks - Yahoo Finance
Franklin Resources Inc. Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):